文献速递胸部肿瘤放疗放疗物理与技术

非小细胞肺癌放化疗中放射性淋巴细胞减少与年龄、肺V5及XRCC1 rs25487基因型的关联

Radiation-induced lymphopenia during chemoradiation therapy for non-small cell lung cancer is linked with age, lung V5, and XRCC1 rs25487 genotypes in lymphocytes.
PubMed 文献 · Radiother Oncol · 2020-09-09

本研究在非小细胞肺癌光子与质子放疗联合化疗的随机临床试验中,分析178例患者,发现年龄较大、肺V5较高及XRCC1 rs25487 AA基因型是治疗期间严重放射性淋巴细胞减少的独立危险因素。三者联合可区分不同风险患者,预测模型有助于识别高危患者以调整治疗。

要点

  • 年龄较大、肺V5较高及XRCC1 rs25487 AA基因型独立关联严重放射性淋巴细胞减少风险。
  • 严重放射性淋巴细胞减少定义为绝对淋巴细胞计数<0.3×10^9细胞/L。
  • 年龄≥56岁、肺V5≥51%及AA基因型联合可区分不同风险患者(P<0.0001)。

核心结论

  • 年龄、肺V5及XRCC1 rs25487 AA基因型均与严重放射性淋巴细胞减少风险相关,预测模型有助于识别高危患者以调整治疗。

研究设计与样本

  • 在非小细胞肺癌光子与质子放疗联合化疗的随机临床试验中,对178例患者的外周血淋巴细胞进行XRCC1 rs25487基因分型。
  • 严重放射性淋巴细胞减少定义为绝对淋巴细胞计数<0.3×10^9细胞/L,采用单因素和多因素分析识别独立危险因素。

主要发现

  • 单因素分析显示年龄较大、肿瘤较大、肺V5和平均肺剂量较高、心脏V5和平均心脏剂量较高与治疗期间严重放射性淋巴细胞减少相关(P<0.05)。
  • XRCC1 rs25487 AA基因型与治疗期间严重放射性淋巴细胞减少风险增加相关(AA vs. 其他:HR=1.665,95%CI 1.089-2.500,P=0.018)。
  • 多因素分析显示年龄较大(HR=1.031,95%CI 1.009-1.054,P=0.005)、肺V5(HR=1.039,95%CI 1.023-1.055,P<0.0001)和AA基因型(AA vs. 其他,HR=1.768,95%CI 1.165-2.684,P=0.007)独立关联严重放射性淋巴细胞减少发生率较高。
  • 年龄≥56岁、肺V5≥51%和XRCC1 rs25487 AA三个危险因素可区分患者发生严重放射性淋巴细胞减少的不同风险(P<0.0001)。

关键数值与推荐

  • 严重放射性淋巴细胞减少定义为绝对淋巴细胞计数<0.3×10^9细胞/L。
  • XRCC1 rs25487 AA基因型与严重放射性淋巴细胞减少风险增加相关(AA vs. 其他:HR=1.665,95%CI 1.089-2.500,P=0.018)。
  • 多因素分析中年龄(HR=1.031,95%CI 1.009-1.054,P=0.005)、肺V5(HR=1.039,95%CI 1.023-1.055,P<0.0001)和AA基因型(HR=1.768,95%CI 1.165-2.684,P=0.007)为独立危险因素。
  • 风险分组标准:年龄≥56岁、肺V5≥51%和XRCC1 rs25487 AA,可区分不同风险(P<0.0001)。

临床怎么用

  • 对于非小细胞肺癌放化疗患者,可评估年龄、肺V5及XRCC1 rs25487基因型以识别严重放射性淋巴细胞减少高危患者,从而考虑调整治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & PURPOSE: We investigated clinical and genetic factors associated with severe radiation-induced lymphopenia (RIL) in a randomized clinical trial of photon vs. proton radiation, with chemotherapy, for non-small cell lung cancer. METHODS: XRCC1 rs25487 was genotyped in lymphocytes from serial peripheral blood samples. Severe RIL was defined as absolute lymphocyte count (ALC) < 0.3 × 109 cells/L. Univariate and multivariate analyses were used to identify independent risk factors, which were then used to group patients for risk of severe RIL. RESULTS: Univariate analysis of the 178 patients in this analysis showed that older age, larger tumors, higher lung V5 and mean lung dose, and higher heart V5 and mean heart dose were associated with severe RIL during treatment (P < 0.05). The XRCC1 rs25487 AA genotype was also associated with increased risk of severe RIL during treatment (AA vs. others: hazard ratio [HR] = 1.665, 95% confidence interval [CI] 1.089-2.500, P = 0.018). Multivariate analyses showed that older age (HR = 1.031, 95% CI 1.009-1.054, P = 0.005), lung V5 (HR = 1.039, 95% CI 1.023-1.055, P < 0.0001), and AA genotype (AA vs. others, HR = 1.768, 95% CI 1.165-2.684, P = 0.007) were independently associated with higher incidence of severe RIL. These three risk factors (age ≥ 56 years, lung V5 ≥ 51% and XRCC1 rs25487 AA) distinguished patients at different risk of developing severe RIL (P < 0.0001). CONCLUSIONS: Age, lung V5 and XRCC1 rs25487 AA were all linked with risk of severe RIL. Our predictive risk model may be helpful for identifying patients at high risk of severe RIL so that treatment can be modified.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Xie X, Lin SH, Welsh JW, et al. Radiation-induced lymphopenia during chemoradiation therapy for non-small cell lung cancer is linked with age, lung V5, and XRCC1 rs25487 genotypes in lymphocytes. Radiother Oncol. 2020. PMID: 32916236. doi:10.1016/j.radonc.2020.09.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。